First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering
October 06, 2022 21:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference
September 28, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
September 19, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference
September 14, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation
September 07, 2022 07:00 ET
|
First Wave BioPharma, Inc.
Data suggest technology provides improved delayed-release profile that ensures adrulipase is delivered to targeted areas of the GI tract First Wave BioPharma expects to initiate Phase 2 trial...
First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract
August 31, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
August 29, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Reverse Stock Split
August 25, 2022 12:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Global Cystic Fibrosis Market Report 2022-2030 - Expanding Therapeutic Options is Expected to Drive Market Growth
August 03, 2022 08:03 ET
|
Research and Markets
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
First Wave BioPharma, Inc. Announces Private Placement
July 15, 2022 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...